We designed a novel experimental approach to probe the sequence space available for HIV-1 evolution. Selective pressure was put on conserved HIV-1 genomic sequences by means of RNA interference (RNAi). Virus escape was monitored in many parallel cultures, and we scored the mutations selected in the RNAi target sequences. The experimentally induced sequence variation closely resembles the sequence variation of natural HIV-1 strains. This indicates that we actually mapped a restricted area of sequence space compatible with virus replication.
The HIV-1 RNA genome is rapidly evolving and, although its sequence heterogeneity is widely recognized, its biological origins and consequences are poorly understood. Sequence variability at the population (interhost) and the individual (intrahost) level stems mainly from the inherent infidelity of the reverse transcriptase enzyme that lacks a proofreading activity. The high HIV-1 replicative turnover, the relative large size of the viral quasispecies population in an infected individual, and the propensity for recombination all add to the viral capacity to adapt to immunological, pharmaceutical, or other selection pressures. Despite the high evolution rate of HIV-1, there are indications that its evolution is not unlimited but confined to a restricted sequence space. We tried to assess the actual sequence space available for HIV-1 in a novel experimental setting.
The evolutionary capacity of HIV-1 was probed by putting a strong selective pressure on highly conserved sequences within the HIV-1 genome and comparing the natural with the selected variation. We used RNAi by means of short hairpin RNA (shRNA) inhibitors to target highly conserved 19-nucleotide sequences within the HIV-1 RNA genome [1] . Multiple cell culture infections were followed to select for viral escape variants. Details of this massive virus evolution study can be found in another article [2] . We compiled the RNAi-resistant mutations that were selected (approximately 500 sequences) with four shRNA inhibitors ( Fig. 1a ) and compared this with the variation observed in 625 natural HIV-1 strains.
We grouped all escape data with respect to the position of the acquired mutations within the 19-nucleotide targets, which yields a typical pattern (Fig. 1b) . In theory, 19 Â 3 ¼ 57 point mutations are possible per target, which means 228 escape possibilities for the four targets. However, we scored only a restricted set of 36 escape routes. Some target positions are highly preferred for acquisition of escape mutations, whereas others are strongly avoided, especially at both ends of the target (positions 1, 2, 18, 19) . The lack of escape mutations at the target ends is most likely dictated by the RNAi mechanism, which is known to allow mismatches between the siRNA effector and the target sequence at these sites [3] [4] [5] [6] [7] [8] . However, we also observed considerable variation in escape pattern for the central target domain (positions 3-17) that cannot be explained by properties of the RNAi mechanism. As we selected the most conserved viral target sequences for the RNAi-therapeutic approach [1, 5, 7] , we checked whether the induced sequence variation would mimic the limited sequence variation present in natural HIV-1 strains in the Los Alamos database. We observed a striking similarity between the RNAi-induced sequence variation ( Fig. 1b ) and natural sequence variation (Fig. 1c ). These results imply that only a selective set of HIV-1 variants are allowed to evolve, both in nature and under RNAi pressure. This also indicates that the HIV-1 variants that are not selected in vitro and in vivo represent viruses with suboptimal replication capacity and fitness. This idea is further supported by the preponderance of silent codon changes among the RNAi-resistant viruses [2] . These results suggest that HIV-1 evolution already reached the outer limits of the allowed sequence space, at least for the highly conserved domains that were probed in this study.
Several studies previously suggested that HIV-1 evolution is restricted to a relatively small domain of sequence space. Most importantly, Lukashov and Goudsmit [9] compared HIV-1 subtype B sequences early in the Amsterdam HIV-1 epidemic versus 10 years later. They described that the high evolution rate of HIV-1 leads to a steady increase in synonymous distance from the consensus sequence, but the nonsynonymous distance remained constant over time. It was concluded that HIV-1 sequences fluctuate within a sequence space with fixed distance from the subtype consensus. This study focused on the V3 domain of the Envelope protein, which may be particularly constrained in function as it is a major determinant for receptor/co-receptor interactions and the key determinant of the CCR5-CXCR4 coreceptor switch.
In natural infections, cytotoxic T lymphocytes (CTLs) put pressure on different HIV-1 protein epitopes. There is accumulating evidence that some of the Gag epitopes tolerate only limited sequence variation because of a fitness cost [10] . These fitness problems also explain the reversion of modified CTL target sequences to the consensus sequence upon HIV-1 transmission to a new host [11] [12] [13] . These in-vivo results strongly argue against unremitting adaptation of HIV-1 to host immune pressures and strongly support the idea of restricted HIV-1 evolution. Similar fitness losses have been described for drug-resistant variants of the Protease enzyme [14, 15] , variation within the Tat protein [16] and the Integrase enzyme [17] . Protease sequences can, in fact, be subject to dual pressure from antiretroviral therapy and CTLs [18] . A complicating factor is that compensatory mutations are able to mask the deleterious effects of another mutation. This has been described for CTL-escape mutations in the Gag protein [19] and drug-resistance mutations in the viral Protease enzyme [7, 20] . Such compensatory changes can even be selected in vitro and in vivo in the absence of drug pressure, demonstrating that repair of enzyme function and viral fitness is the driving force [21] .
Our current findings also have important implications for the design of improved antiviral RNAi strategies, in particular with respect to attempts to avoid viral escape. We previously used one simple criterion to select target sites: optimal conservation of the targeted sequence among virus strains [1] . We now propose additional criteria to stipulate target selection. First, selection of the most conserved targets should focus on the center of the 19-nucleotide target domain (positions 3-17), as RNAi is tolerant for sequence variation at the termini of the target. Second, this 3-17 domain should be selected with the least number of silent codon positions (mostly third codon positions). Third, it seems beneficial to find targets enriched for AUG and UGG codons encoding methionine and tryptophan, respectively, because these are the only two codons that lack options for silent escape. Fourth, our data suggest that one can actually use the available information on natural HIV-1 sequence variation in the design of improved shRNA inhibitors, as this should define the available sequence space for HIV-1 that can be used to obtain RNAi resistance. Specifically, one could define targets that restrict sequence variation to only one or two positions, in which case one could anticipate these viral escape routes and design a limited set of second generation shRNAs to block these escape routes [22] . These considerations are of importance for the development of a durable RNAi-based gene therapy for HIV-AIDS. The 288 amino acid (aa) HIV-1 integrase (IN) catalyzes the integration of reverse transcribed viral DNA into the host cell chromosome [1, 2] and consists of three structural domains, namely the N-terminal domain (aa 1-49) containing a HHCC motif (His12-His16-Cys40-Cys43) [3] ; the central core domain (aa 50-212) containing the DDE catalytic motif (Asp64-Asp116-Glu152) [4] ; and the C-terminal domain (aa 213-288), which is considered to play a role in DNA-binding activity [5] and oligomerization [6] .
Reduction in INI susceptibility has been shown in vitro [7, 8] and, in vivo in treatment-failing regimens [7, [9] [10] [11] . Resistance to RAL develops via two main pathways: N155H or Q148K/R/H, and possibly through another pathway, Y143R/C [7, [9] [10] [11] . For each of these pathways, additional mutations were observed, either resulting in more pronounced susceptibility reduction, or restoring viral fitness [7] . From the EVG phase II clinical trials, mutations E92Q, E138K, Q148R/K/H, or N155H were identified [12] , suggesting clinically significant crossresistance between RAL and EVG, which has been confirmed in vitro [12, 13] . Today, 64 mutations at 44 positions within the HIV-1 IN gene have been associated with integrase drug resistance [14] . In addition to drug-selected mutations, natural polymorphisms are thought to be associated with INI resistance (e.g. S17T, M50T, L74I, A91V, E92G, S119G, T124N, and S195C) [14, 15] . It is unknown whether clade-specific polymorphisms affect the selection of an INI-resistance pathway.
Although several studies have explored the genotypic variability of the integrase gene in both B and non-B subtype HIV samples [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] , no in-vitro phenotypic susceptibility data are available. In vivo, however, RAL phase III trials were performed in Europe, Asia-Pacific, Peru, and North and South America; hence, it is likely that non-B subtypes were included in these trials. No reduced treatment response was reported for the non-B subtypes [9, 11] . For EVG, no subtype-specific phenotypic studies have been reported.
In this study, we explored both the genetic variability and the phenotypic susceptibility to RAL and EVG. [15, 17, 18, 22] . None of the samples contained the primary RAL or EVG resistance-associated mutations (T66I, E92Q, Y143R/C, Q148K/R/H or N155H). Other mutations reported to be associated with INI resistance were present as natural polymorphisms at varying prevalence. Some polymorphisms were present in only one subtype (L68I, L74M, S119R, S119G, E138D, V151I, D232N in subtype B, T97A only in subtype A1, and V249I only in subtype C), whereas other polymorphisms were present in all subtypes (V72I, L101I, T124N, and V201I). Moreover, L101I occurred as the consensus for subtype C and as a polymorphism for the other subtypes. V201I is polymorphic in subtype B but present as the consensus for all other subtypes. Finally, certain polymorphisms were present in some but not all subtypes (S17T, M50T, L74I, K111T, T112I, M154I, K156N, V165I, G193R, S195C, and I203M).
All samples were tested for phenotypic susceptibility to RAL and EVG. SDM Q148R served as positive control (fold change of 17.85 AE 2.77 to RAL and 88.94 AE 9.02 to EVG, Fig. 1 
Introduction
In large cohorts of patients, the HIV-1 reservoir size is usually estimated by quantifying total HIV-DNA in peripheral blood mononuclear cells (PBMCs) [1, 2] . This can differentiate groups of patients, for example, longterm non-progressors (LTNPs) have a lower HIV-DNA level than patients who do not control HIV infection [1, 2] .
However, only 2-5% of the body's lymphocytes are present in the blood, whereas gut-associated lymphoid tissue (GALT) contains most of the body's lymphoid tissue, therefore constituting an immense compartment for persistent HIV-1 infection [3] [4] [5] . GALT is the first site of rapid and extensive spread of HIV and of the most substantial CD4þ T-cell depletion at all stages of HIV disease in humans [6, 7] . Conversely, LTNP have normal GALT CD4þ T-cell levels [8] and undetectable HIV-RNA [9] . HIV-1 replication in GALT is decreased in patients receiving highly active antiretroviral therapy (HAART), but recovery of intestinal CD4þ T-cell numbers is variable among patients [10] . HIV-RNA and replication-competent HIV-1 in GALT can be detected in patients with successful HAART. Suppression of GALT HIV-RNA and restoration of mucosal CD4þT lymphocytes during HAART are more effective in primary infection than chronic infection [8] . Only a few studies have quantified mucosal HIV-DNA, in recently infected or aviremic patients [3] [4] [5] 7] .
The aim of our study was to quantify the mucosal HIV infection level for different patient groups, including LTNP, and to compare it with the PBMC HIV infection level.
Patients and methods
Twenty-seven HIV-infected patients were included (Table 1) ; three patients within 90 days of onset of acute retroviral illness, two patients starting treatment during primary infection, five patients untreated with chronic infection (>12 months of infection), eight patients on effective treatment initiated during chronic infection (HIV-RNA < 50 copies/ml sustained for over 6 months), one patient chronically infected and on effective treatment for the primary infection, five patients in 'remission' [i.e. patients who initiated HAARTwithin 16 weeks of onset of primary infection symptoms were treated between 25 and 80 months, and have had sustained viral and immunological control for over 9 months since treatment interruption (HIV-RNA < 50 copies/ml and >500 CD4þ T cells/ml)] and three LTNP (i.e. untreated patients infected by HIV for over 6 years with >600 CD4þ T cells/ml, HIV-RNA < 2000 copies/ml).
Paired blood samples and four rectal biopsies (approximately 2 ml) were taken on the same day from each patient. All rectal endoscopic biopsies were performed in the same site to avoid potential regional variation among patients. The local ethics committee approved the study and patients provided their written informed consent.
PBMCs were separated from whole blood by Ficoll-Hypaque density gradient (Amersham Biosciences, Uppsala, Sweden). PBMCs and rectal biopsies were stored at À808C before use. Total DNA was extracted from PBMCs using QIAamp DNA mini kit (QIAGEN, Courtaboeuf, France) and from rectal tissues using QIAamp tissue kit, according to the manufacturer's instructions. Total HIV-1 DNA, including integrated and unintegrated HIV-DNA, was quantified in PBMCs and rectal biopsies by real-time PCR (amplification of LTR region -ANRS assay, sensitivity threshold six copies/PCR) [11] . Rectal tissue was also collected from the same site for histopathological assessment and no confounding condition such as inflammation was observed. Spearman test was performed for correlation.
Results
We studied reproducibility of HIV-DNA quantification in rectal biopsies. We performed two PCRs using the extract of each of the four rectal biopsies taken the same day and calculated the coefficients of variation for each patient. HIV-DNA was detected in all rectal biopsies and could be reproducibly quantified in the four biopsies with low intra-patient variability (coefficients of variation between 2.4% and 9.8%). We then calculated the mean of these eight results for each patient.
We observed a wide range of values in rectum between groups (1.8-4 log copies/10 6 rectal cells) ( Table 1 ). The level of HIV-DNA in PBMCs was positively correlated with that in rectal biopsies (r ¼ 0.841, P < 0.0001).
Low blood and rectal HIV-DNA levels were observed for LTNP (group 7) (ranges: 2.1-2.3 log copies/10 6 PBMC and 1.9-2.1 log copies/10 6 rectal cells, respectively).
They were similar to those for patients in 'remission' (group 6) and the chronically infected patient on effective HAART initiated during primary infection (group 5).
Discussion
The estimation of GALT reservoirs could help to understand HIV pathogenesis, especially in patients with long-term control of HIV infection. Rectal biopsies obtained during endoscopy are highly appropriate for the investigation of that reservoir because, firstly, they are a safe, painless and minimally invasive means of obtaining GALT tissue; secondly, the rectal lamina propria is an effector site of preferential accelerated depletion of CD4 lymphocytes during primary infection, playing a causal role in the development of mucosal immunodeficiency [6] . We demonstrated that our sensitive assay for HIV-DNA quantification can be used even for very small rectal biopsies, with a good reproducibility.
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This is the first study, to our knowledge, showing that the blood HIV-DNA level, which predicts disease progression [1] , reflects the HIV-DNA level in a mucosal tissue such as rectum for patients at different stages of HIV infection, both untreated and efficiently treated. We confirmed previous observations in aviremic patients [3, 5] . Similar studies need to be carried out with other GALT and phylogenetic studies on HIV-DNA quasispecies in the blood and rectum will be useful to study the viral dynamics.
Moreover, our preliminary findings are the first to show that LTNP seems to have a very low HIV-DNA level not only in blood, but also in some large mucosal reservoirs. Surprisingly, similar levels are observed in the chronically infected patient on effective HAART initiated during primary infection and patients in 'remission'. Veazey and Lackner [12] have already suggested that treatment should be initiated as soon as possible to limit mucosal damage, enhancing mucosal repair and regeneration. Although it is unlikely that such treatment regimens can be implemented in humans on a large scale, our preliminary findings suggest that early and prolonged antiretroviral treatment may also reduce HIV cellular reservoirs as much and as quickly as possible. physicians responsible for HIV- conflict-affected population using focus groups (n U 40) and semi-structured interviews (n U 11). Patient concerns include security attending clinics, food security, distance to health centers and access to health providers. During periods of famine and flooding, the lack of food security and only single daily meals makes taking multiple doses impossible. Possible facilitating strategies included mobile teams, increased security and regularity of drug stocks.
Distribution of combination antiretroviral therapy (cART) to HIV-positive individuals in complex emergencies is imperative from a public health and human rights perspective [1] . Patients receiving cART in armed conflicts have demonstrated clinical outcomes similar to those of patient in politically stable settings [2, 3] . Numerous qualitative studies have assessed structural, cultural and socioeconomic barriers to cART adherence in resource-limited settings [4] . However, none have examined these within the context of armed conflict. We aimed to examine patient-important barriers to cART adherence in a conflict-affected area of northern Uganda. We developed a semi-structured interview protocol that prompted respondents to discuss a range of factors that influence their adherence to cART, including: illness, political security, food insecurity, disclosure, adverse events, healthcare infrastructure and transportation. We conducted five-focus group discussions with HIVpositive IDP camp residents (n ¼ 40) and semi-structured interviews with healthcare workers (n ¼ 11) at the Katakwi Health Centre.
Each focus group discussion was facilitated by a physician fluent in English, Swahili and Ateso. Focus-group sessions lasted 90 min, and were audiotaped and transcribed in duplicate. Major themes were coded for retrieval and analysis. Our study was approved by the Ethics Review Board of the Mbale Regional Referral Hospital, Uganda.
Of the 40 cART patients interviewed, exactly half were women (n ¼ 20 Transportation was frequently cited as a patient barrier to cART adherence. Factors prohibiting good adherence included weather, transportation cost and illness stage:
Having already experienced or witnessed torture, abduction or killings, respondents cited insecurity and fear as causes of cART nonadherence:
Insecurity results in loss of drugs or forgetting to pick them in time from your house. If you hear the alarm, you just take off.
Clients fear meeting Karamojong cattle rustlers on the way, and fail to keep appointments or cannot wait in the line at the clinic beyond a certain time.
The poor security situation results in loss of medical forms, running far away from the clinic and forgetting ARVs in the hurry to escape.
Healthcare infrastructure and, specifically, lack of human resources and drugs were frequently cited as barriers to treatment adherence:
Health workers are either very few or not available, and yet you cannot get a drug refill before being seen by a health worker.
The line is very long and you sometimes wait the whole day before you are seen, even if you arrived at the clinic as early as 5:00 a.m.
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Second-line drugs are not available in our health units hence clients on these miss their dose. They have to travel to Soroti or Mbale to purchase these medicines or access.
Focus groups emphasized the role flooding and patient dependence on caregivers for food security may have on nonadherence to cART:
The communities following the floods can only afford one meal a day (evening meal), hence will ignore the morning dose and only take the evening dose.
Those people who are disabled (sick) miss their doses when they fail to get someone to give them food. We cannot share our little food with them all the time even if we know that they need our support.
To our knowledge, this study represents the first reported assessment of patient-important barriers to cART adherence in a conflict setting, and should be of interest to HIV patient groups, clinicians and the international community. Transportation (poor weather, high cost and limited mobility); human security (real and feared); health infrastructure (limited drug stock and human resources) and food insecurity (due to floods and caregiver dependency) were cited as major factors influencing cART nonadherence in the Teso region. Our findings build on a recent study [3] evaluating clinical cART outcomes in northern Uganda and provide a nuanced explanation of reasons for nonadherence in this population. Understanding patient-important barriers to cART adherence is critical to effectively scaling up cARTaccess. The logistical and security concerns highlighted by participants in this study merit attention from public health officials and clinicians to aid HIV-positive populations in northern Uganda. Efforts to ensure uninterrupted care in these populations remain a core challenge. As populations return to their villages, efforts to retain patients using motorcyclebased counsellors and health workers are effective strategies to ensure continued care.
